Alkermes Stock Price, News & Analysis (NASDAQ:ALKS)

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALKS shares.
View ALKS analyst ratings or view top-rated stocks.

7 analysts have issued 12 month price targets for Alkermes' shares. Their ALKS share price targets range from $28.00 to $35.00. On average, they predict the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 32.9% from the stock's current price.
View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts.

Alkermes' stock was trading at $26.13 on January 1st, 2023. Since then, ALKS shares have decreased by 7.0% and is now trading at $24.29.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our ALKS earnings forecast.

Alkermes plc (NASDAQ:ALKS) announced its quarterly earnings results on Wednesday, October, 25th. The company reported $0.50 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.19. The company earned $380.94 million during the quarter, compared to analysts' expectations of $366.18 million. Alkermes had a trailing twelve-month return on equity of 11.41% and a net margin of 13.50%.

ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Subversive Mental Health ETF (SANE), iShares Neuroscience and Healthcare ETF (IBRN), Horizon Kinetics Medical ETF (MEDX), ALPS Medical Breakthroughs ETF (SBIO), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE) and Putnam BioRevolution ETF (SYNB).

Alkermes updated its FY23 earnings guidance on Wednesday, November, 15th. The company provided earnings per share (EPS) guidance of $1.57-$1.75 for the period, compared to the consensus EPS estimate of $1.58.

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Alkermes' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (7.04%), Hardman Johnston Global Advisors LLC (3.37%), Primecap Management Co. CA (2.33%), Bank of New York Mellon Corp (1.66%), Charles Schwab Investment Management Inc. (1.30%) and Morgan Stanley (1.21%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends.

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.